Navigation Links
Singapore National Science and Technology Awards
Date:9/13/2007

ontrolling gene expression. His work, which is a valuable resource for the global stem cell community, is highly cited. At 36, Dr Ng from the Genome Institute of Singapore and the National University of Singapore is one of the youngest recipients of the National Science Award.

  • Assoc Prof Uttam Surana from the Institute of Molecular and Cell Biology examined the intricacies of cell division, one of the most fundamental activities of living cells that allow them to multiply. He uncovered novel schemes used to regulate cell division and to maintain chromosome stability in yeast cells. Using his understanding of cell cycle coordination, he designed genetic screens to identify compounds that could prevent division and induce cell death in cancer cells.

  • The team comprising Prof AJ (Jon) Berrick and Assoc Prof Wu Jie from the National University of Singapores Department of Mathematics uncovered deep connections between algebraic topology and the theory of braids. This fundamental work which brought together two branches of mathematics lays the foundation for other researchers to apply the mathematical structures to situations requiring precise control of complex multi-object multi-dimensional movement, as in the case of air traffic control, robotic motion and the folding of proteins to create new drugs.

National Technology Award 2007

The two teams receiving the National Technology Awards this year reflect highly innovative technology development in the private and public research laboratories in Singapore.

  • The team from the Institute for Infocomm Research invented the Advanced Audio Zip, a flexible audio coding tool that is capable of compressing any music file (such as a CD track) to less than half of its original size, as well as restore every bit of the original data during playback without any loss or distortion. At the same time, the coder allows fine-grain bitrate scal
    '/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5

Related biology news :

1. Papers of DNA Pioneer and Nobel Laureate Francis Crick Added to National Library of Medicine’s Profiles in Science Web Site
2. International trial of two microbicides begins
3. International HapMap consortium expands mapping effort
4. BioMed Central welcomes the new National Institutes of Health public access policy
5. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
6. Canadian youth 4th highest in international obesity study
7. International Team Determines Geographic Origin of Leprosy
8. Team of international scientists departs today to discover the unknown in Chinas Himalayan region
9. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
10. Tropical dry forests receive international recognition
11. Open Source Biotechnology alliance for international agriculture
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
Other Biology Technology:Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial 2New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 2New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 3New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 4New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 5New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 6New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 7New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence 8Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period 2